Articles tagged with Liver Damage
Researchers identify key protein interactions that control the body's immune response during liver transplantation, leading to improved transplant survival rates. The study found that a specific communication pathway between CEACAM1 and TIM-3 proteins plays a crucial role in controlling the immune response.
Hospital admissions for alcohol-related hepatitis increased dramatically during the pandemic, particularly among younger patients and women. Researchers found a 12.4% rise in cases in 2020 compared to 2019 levels.
Researchers investigated premature senescence in biliary atresia and assessed senotherapies. They found that human allogenic liver-derived progenitor cells reduced early markers of senescence and improved liver disease in a preclinical model, providing encouraging results for pediatric biliary cirrhosis treatment.
Researchers found that obese patients with mild traumatic brain injuries had higher levels of inflammatory biomarkers and prolonged symptoms compared to those with healthy body mass indexes. The study suggests that obesity may mediate the inflammatory response and symptoms in mTBI patients.
A clinical trial using DIALIVE, a novel liver dialysis device, demonstrated significant improvements in all main underlying pathophysiological mechanisms of acute-on-chronic liver failure. Treatment resulted in accelerated resolution of ACLF and sustained improvement in biomarkers.
A new substudy of the STEP TEENS trial shows that semaglutide significantly reduces levels of liver enzymes, including alanine aminotransferase (ALT), which are indicators of liver damage. The study found improvements in ALT levels with weight loss of ≥10%.
A research team at Hokkaido University has developed a system to deliver antioxidants to mitochondria in the liver, reducing oxidative stress and damaging caused by ROS. The system, called CoQ10-MITO-Porter, was found to be more effective when downsized particles were used.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
Researchers developed an ASO treatment that improves bile duct development and prevents fibrosis and cell death in animal models of Alagille syndrome. The study offers a potential therapeutic option for patients with this condition, potentially bypassing the need for liver transplant.
Researchers found that after 96 weeks, some patients achieved loss of detectable HBsAg and reduced liver inflammation levels, indicating functional cure. The study suggests that discontinuing long-term antiviral therapy may be more effective than continuing it for certain patients.
A recent study found that the mitochondrial antioxidant MitoQ can reverse the detrimental effects of HIV and antiretroviral therapy on organs such as the brain, heart, and liver. The researchers used humanized mice infected with HIV and treated them with MitoQ for three months.
Researchers from Kyushu University found that the single mechanosensitive protein VGLL3 induces fibrosis, thickening and scarring tissue. The study suggests targeting this protein could lead to new treatments against fibrosis.
A US FDA mandate to limit acetaminophen dosage in pills combining it with opioids significantly reduced hospitalizations and acute liver failure cases. Researchers found a persistent decline in yearly rates of these cases after the mandate was implemented in 2014.
A new study by Weill Cornell Medicine found that the FDA's mandate to limit opioid-acetaminophen combinations resulted in significant reductions in liver injuries. The mandate, implemented in 2014, limited the dosage of acetaminophen in these drugs, leading to a decline in hospitalizations and acute liver failure cases.
A new study shows that patients with liver cirrhosis have a lower immune response to COVID-19 vaccines, but this does not affect the vaccines' effectiveness. Age, type of vaccine, and viral hepatitis etiology also play a role in immune responses.
A team of researchers from MedUni Vienna has identified the polymeric immunoglobulin receptor (pIgR) as a key player in protecting against alcohol-induced liver damage. The study found that pIgR-mediated secretion of antibodies in the intestines helps to prevent bacterial translocation and inflammation in the liver.
Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.
A new study finds that COVID-19 patients exhibit higher liver stiffness months after infection, indicating possible long-term liver damage. The study also suggests that even pre-pandemic patients showed increased liver stiffness, likely due to changing referral patterns during the pandemic.
Research from Rutgers University suggests that high-dose green tea extract may cause liver damage in individuals with specific genetic variations. The study found that two genetic variants, COMT and UGT1A4, were associated with increased liver stress after a year of consuming the supplement.
Researchers found that a genetic mutation associated with liver disease confers different levels of risk depending on a patient's diabetic status. In diabetic patients, the mutation predisposes them to nonalcoholic fatty liver disease, but in nondiabetic patients, it protects against liver disease.
A study in Japan reveals that universal screening methods for biliary atresia, a rare and severe lung condition in infants, are cost-effective. The research found that stool color card screening and direct bilirubin testing gained significant clinical benefits and saved lives.
A retrospective study of 26,000 patients with cirrhosis found that receiving a third dose of the COVID-19 vaccine reduced overall and severe cases by 80% and 100%, respectively. This suggests that a third dose can overcome vaccine hyporesponsiveness in patients with cirrhosis.
Researchers developed a non-invasive algorithm to identify patients with compensated cirrhosis at highest risk for severe complications. The online calculator uses widely available laboratory parameters and is simple, non-invasive, and cost-effective.
A study identifies a molecule called NIK that promotes the growth of bile duct cells in the liver, leading to scarring and liver fibrosis. Removing NIK or blocking its action with inhibitors may prevent disease progression.
A new Chinese Medical Journal review article elucidates the potential contributors to non-alcoholic fatty liver disease (NAFLD) progression, highlighting the role of bile acid and sphingolipid biology. Researchers summarize current understanding of NAFLD, its progression, and potential therapeutic strategies.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.
Researchers have identified Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) as a key regulator in the development and progression of nonalcoholic steatohepatitis. IGF2BP2 overexpression was found to induce liver steatosis, inflammation, and injury in healthy mice, while knockdown improved NASH pathogenesis.
A new study suggests that acetate produced by the liver diffuses into the intestines, supporting bacterial growth and causing imbalanced microbiota. This imbalance does not appear to play a major role in alcoholic liver disease risk.
The study investigated the effects of combined endocrine-disrupting chemicals (EDCs) on liver function and metabolic homeostasis in mice models. Significant changes were observed at high EDC exposure levels, including liver weight increase, lipid buildup, and elevated blood glucose levels.
Individualized, comprehensive treatment approaches and risk stratification of patients are crucial for effective treatment of MAFLD. Lifestyle modifications and pharmaceutical therapeutics combining to treat the condition.
Researchers found that lactating mothers expose their pups to triclosan, leading to early signs of liver damage that can progress to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Exposure to triclosan in early life may lay the groundwork for future development of fatty liver disease.
The new grant aims to address structural racism and discrimination affecting Asian-Americans with chronic hepatitis B virus infection and liver cancer. Researchers will examine factors such as socio-historical hardship, segregation, and mistrust of the health system to improve quality of care.
A study found that Dragon's Blood alleviates brain damage, hematopoietic dysfunction, and gastrointestinal damage caused by radiation in rats. The compound regulates metabolism and redox homeostasis to protect the liver from damage.
Youth substance use declined during the COVID-19 pandemic, as teens had limited access to peers and substances due to stay-at-home orders. This reduced risk of substance use is attributed to increased social isolation from peers, which may have a negative impact on mental health.
A novel study has identified metabolic defects, impaired protein secretion, and altered phosphoproteomic signatures in alcohol-associated cirrhosis and hepatitis. These findings may lead to the development of new diagnostic and therapeutic approaches for a disease with limited treatment options.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Research finds that excessive mitochondrial damage caused by alcohol exposure can lead to chronic liver disease. Mitochondrial depolarization triggers mitophagy, a process removing damaged mitochondria; however, constant removal causes additional liver tissue damage.
Researchers at CIC bioGUNE identified microRNA 873 as a potential therapeutic agent for acute liver failure due to APAP overdose. The study found that anti-miR-873-5p treatment rescues the liver and extends the therapeutic window by 24 hours.
A new study systematically reviews data on PFAS exposure and liver damage, linking three commonly detected PFAS to elevated levels of a liver enzyme, ALT. The research suggests a potential link between PFAS and non-alcoholic fatty liver disease (NAFLD), a growing public health crisis affecting 25% of adults worldwide.
A Canadian study of over 12,000 hospital admissions found that updated product label changes did not reduce rates of accidental acetaminophen overdose. The study suggests additional measures are needed to prevent these episodes beyond just labeling changes.
This year's Experimental Biology 2022 meeting features groundbreaking studies on COVID-19 vaccine-associated symptoms in non-menstruating people, a plant compound showing promise for alleviating food allergies, and the potential of omega-3s to boost immunotherapy's cancer-fighting power. Researchers also explore the safety of using CBD...
Researchers at Osaka City University found that globin family members can suppress liver inflammation and fibrosis in mice. The proteins' antioxidant capacity was greater than glutathione and vitamin C, suggesting a potential therapy for liver fibrosis.
Research in the Journal of Hepatology suggests that COVID-19 vaccines are unlikely to cause liver injury, but liver transplant patients may experience delayed care due to the pandemic. The study found that vaccinated patients with liver disease had a lower antibody response compared to healthy patients.
Researchers have identified a molecular mechanism underlying liver cirrhosis, a deadly disease poorly understood. The discovery, made using genetically modified mice, reveals that the lack of MCRS1 protein leads to bile acid accumulation and fibrosis, opening new avenues for treatment.
A study found that spaceflight alters liver gene expression and reduces antioxidant capacity in mice, leading to increased oxidative stress. However, exposure to artificial gravity can mitigate some of these effects, suggesting potential for dietary supplementation to offset changes during spaceflight.
A cohort study of 165 patients with hepatitis C-related hepatocellular carcinoma found that treating the virus with direct-acting antivirals reduces tumor progression and metastasis. The study showed a 72% reduction in tumor progression and an 88% reduction in risk of death from HCC.
Researchers found that albino mice with a mutated tyrosinase gene are more susceptible to non-alcoholic steatohepatitis (NASH) than black mice. This study provides new insights into the genetic factors contributing to NASH and its progression.
The American Gastroenterological Association (AGA) has released new clinical guidelines that recommend against extensive preprocedural testing to estimate clotting in patients with cirrhosis. This change aims to reduce the risk of morbidity and mortality associated with unnecessary blood clotting tests.
Researchers found that exogenous phosphatidic acid protects against liver injury caused by acetaminophen overdose. PA activates interleukin-6 signaling, which is crucial for reducing liver damage.
A new study found that every extra 1cm in waist circumference increases the odds of advanced fibrosis by 5% in people with type 2 diabetes. Advanced fibrosis is a late stage of non-alcoholic fatty liver disease (NAFLD), which can lead to serious liver damage.
This study compared drugs associated with hepatotoxicity in the FDA's FAERS database, finding that mitochondrial mechanisms are a leading cause of drug-induced liver injury. The top four drugs with the highest risk were associated with mitochondrial mechanisms, and older patients and females were more likely to be affected.
A new biomarker, HBcrAg, has been found to accurately predict viral load in patients with chronic hepatitis B and reflect response to anti-viral treatments. This discovery may lead to improved monitoring methods for CHB, enabling clinical decisions and potentially improving patient outcomes.
A study in mice and human blood samples found that HDL3 protects the liver by blocking gut bacterial signals that cause inflammation. The researchers identified a special type of HDL called HDL3 that is produced by the intestine, which blocks lipopolysaccharide signals that activate immune cells.
Researchers found that high serum levels of human IL-11 in mice with paracetamol toxicity led to liver cell death. However, blocking IL-11 signalling protected against liver damage and promoted survival. The study suggests a restorative effect when using anti-IL11 therapy.
Researchers have developed a simple blood test that can detect acute liver damage earlier than current methods. The test uses gold nanoparticles to target the antioxidant glutathione, which is depleted in damaged liver cells. This early detection could lead to faster recovery and improved treatment outcomes for patients with liver injury.
Cytoglobin has been identified as a key player in delaying liver fibrosis progression in mice. The enhancement of CYGB on hepatic stellate cells or intravenous injection of recombinant CYGB suppresses liver damage and cirrhosis. This discovery holds promise for developing new anti-fibrotic therapy for human chronic liver diseases.
Researchers found that ACSL1 catalyzes CoA conjugation of propionic acid-class NSAIDs, leading to liver injury through covalent binding with hepatic proteins. This variation in hepatic ACSL1 expression may account for individual susceptibility to toxicities.
Researchers have discovered a gene mutation that protects against liver disease and may offer a 'fountain of youth' for French-Canadian families. The PCSK9Q152H mutation has been found to lower bad cholesterol and prevent cardiovascular diseases, allowing individuals to live longer and healthier into their late 80s and mid-90s.
The Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium have developed a glutamate dehydrogenase (GLDH) biomarker to detect drug-induced liver injury in patients with inherited muscle disorders. The FDA has agreed to accept the Qualification Plan for GLDH as an important and accurate measurement of DILI.
Researchers found dihydromyricetin (DHM) activates mechanisms that quickly metabolize alcohol and reduce liver harm. The study supports DHM as a dietary supplement to offset acute and long-term risks of alcohol consumption.